Free Trial

PROCEPT BioRobotics Q4 2023 Earnings Report

PROCEPT BioRobotics logo
$76.02 -2.82 (-3.58%)
As of 01/17/2025 04:00 PM Eastern

PROCEPT BioRobotics EPS Results

Actual EPS
-$0.54
Consensus EPS
-$0.44
Beat/Miss
Missed by -$0.10
One Year Ago EPS
-$0.56

PROCEPT BioRobotics Revenue Results

Actual Revenue
$43.58 million
Expected Revenue
$41.79 million
Beat/Miss
Beat by +$1.79 million
YoY Revenue Growth
+83.30%

PROCEPT BioRobotics Announcement Details

Quarter
Q4 2023
Time
After Market Closes

Conference Call Resources

PROCEPT BioRobotics Earnings Headlines

Spruce Point Capital says short Procept BioRobotics
Grab This Altcoin Before Trump's Crypto Announcement
Grab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which is why I'm recommending ONE coin to all investors right now.
PROCEPT BioRobotics
See More PROCEPT BioRobotics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like PROCEPT BioRobotics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on PROCEPT BioRobotics and other key companies, straight to your email.

About PROCEPT BioRobotics

PROCEPT BioRobotics (NASDAQ:PRCT), a surgical robotics company, focuses on developing transformative solutions in urology in the United States and internationally. The company develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). It also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.

View PROCEPT BioRobotics Profile

More Earnings Resources from MarketBeat